Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Ghanem Atassi
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Anatomy
Living Beings
Chemicals & Drugs
Procedures
Disorders
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
36
Pierré, Alain
21
Léonce, Stéphane
18
Kraus-Berthier, Laurence
16
Guilbaud, Nicolas
14
Tillequin, François
12
Renard, Pierre
11
Skaltsounis, Alexios-Leandros
9
Michel, Sylvie
8
Koch, Michel
8
Caignard, Daniel-Henri
7
Mitaku, Sofia
7
Tucker, Gordon
6
leonce, stephane
6
Boutin, Jean
6
Jan, M
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Ghanem Atassi (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2007: Romero Manel; Renard Pierre; Caignard Daniel-Henry; Atassi Ghanen; Solans Xavier; Constans Pere; Bailly Christian; Pujol Maria Dolors
Synthesis and structure-activity relationships of new benzodioxinic lactones as potential anticancer drugs.
Journal of medicinal chemistry 2007;50(2):294-307.
-
2004: Lisowski Vincent; Léonce Stéphane; Kraus-Berthier Laurence; Sopková-de Oliveira Santos Jana; Pierré Alain; Atassi Ghanem; Caignard Daniel-Henri; Renard Pierre; Rault Sylvain
Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents.
Journal of medicinal chemistry 2004;47(6):1448-64.
-
2003: Li Ying; Wu Jin Ming; Shan Feng; Wu Guang Shao; Ding Jian; Xiao Dong; Han Jia Xian; Atassi Ghanem; Leonce Stéphane; Caignard Daniel Henri; Renard Pierre
Synthesis and cytotoxicity of dihydroartemisinin ethers containing cyanoarylmethyl group.
Bioorganic & medicinal chemistry 2003;11(6):977-84.
-
2002: Kraus-Berthier Laurence; Guilbaud Nicolas; Léonce Stéphane; Parker Tracy; Genissel Patrick; Guillonneau Claude; Goldstein Solo; Atassi Ghanem; Pierré Alain
Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Cancer chemotherapy and pharmacology 2002;50(2):95-103.
-
2001: Léonce S; Pérez V; Lambel S; Peyroulan D; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J A; Pierré A
Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis.
Molecular pharmacology 2001;60(6):1383-91.
-
2001: Kostakis I K; Pouli N; Marakos P; Mikros E; Skaltsounis A L; Leonce S; Atassi G; Renard P
Synthesis, cytotoxic activity, NMR study and stereochemical effects of some new pyrano[3,2-b]thioxanthen-6-ones and pyrano[2,3-c]thioxanthen-7-ones.
Bioorganic & medicinal chemistry 2001;9(11):2793-802.
-
2001: Bongui J B; Elomri A; Seguin E; Tillequin F; Pfeiffer B; Renard P; Pierré A; Atassi G
Synthesis and cytotoxic activity of benzophenanthrolinone analogues of acronycine.
Chemical & pharmaceutical bulletin 2001;49(9):1077-80.
-
2001: Lisowski V; Enguehard C; Lancelot J; Caignard D; Lambel S; Leonce S; Pierre A; Atassi G; Renard P; Rault S
Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents.
Bioorganic & medicinal chemistry letters 2001;11(16):2205-8.
-
2001: Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2573-80.
-
2001: Sittisombut C; Costes N; Michel S; Koch M; Tillequin F; Pfeiffer B; Renard P; Pierré A; Atassi G
Synthesis and cytotoxic activity of benzopyranoxanthone analogues of benz.
Chemical & pharmaceutical bulletin 2001;49(6):675-9.
-
2001: Wu J M; Shan F; Wu G S; Li Y; Ding J; Xiao D; Han J X; Atassi G; Leonce S; Caignard D H; Renard P
Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group.
European journal of medicinal chemistry 2001;36(5):469-79.
-
2001: Melliou E; Magiatis P; Mitaku S; Skaltsounis A L; Pierré A; Atassi G; Renard P
2,2-Dimethyl-2H-anthra[2,3-b]pyran-6,11-diones: a new class of cytotoxic compounds.
Bioorganic & medicinal chemistry 2001;9(3):607-12.
-
2001: Chollet A M; Le Diguarher T; Murray L; Bertrand M; Tucker G C; Sabatini M; Pierré A; Atassi G; Bonnet J; Casara P
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
Bioorganic & medicinal chemistry letters 2001;11(3):295-9.
-
2001: Henlin J M; Boutin J A; Kucharczyk N; Desmet-Beaufort C; Loynel A; Bertrand M; Genton A; Tucker G C; Atassi G; Fauchére J L
From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors.
The journal of peptide research : official journal of the American Peptide Society 2001;57(2):85-96.
-
2001: Li Y; Shan F; Wu J M; Wu G S; Ding J; Xiao D; Yang W Y; Atassi G; Léonce S; Caignard D H; Renard P
Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle.
Bioorganic & medicinal chemistry letters 2001;11(1):5-8.
-
2000: Kostakis I; Ghirtis K; Pouli N; Marakos P; Skaltsounis A L; Leonce S; Caignard D H; Atassi G
Synthesis and cytotoxic activity of 2-dialkylaminoethylamino substituted xanthenone and thioxanthenone derivatives.
Farmaco (Società chimica italiana : 1989) 2000;55(6-7):455-60.
-
2000: Costes N; Le Deit H; Michel S; Tillequin F; Koch M; Pfeiffer B; Renard P; Léonce S; Guilbaud N; Kraus-Berthier L; Pierré A; Atassi G
Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine.
Journal of medicinal chemistry 2000;43(12):2395-402.
-
2000: Aligiannis N; Pouli N; Marakos P; Mitaku S; Skaltsounis A L; Leonce S; Pierre A; Atassi G
Design, synthesis and biological activity of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl) daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo- hexopyranosyl)daunomycinone.
Chemical & pharmaceutical bulletin 2000;48(1):150-3.
-
2000: Kraus-Berthier L; Jan M; Guilbaud N; Naze M; Pierré A; Atassi G
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):297-304.
-
1999: Burbridge M F; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
International journal of oncology 1999;15(6):1155-62.
-
1999: Elomri A; Michel S; Koch M; Seguin E; Tillequin F; Pierré A; Atassi G
Synthesis and cytotoxic activity of 11-nitro and 11-amino derivatives of acronycine and 6-demethoxyacronycine.
Chemical & pharmaceutical bulletin 1999;47(11):1604-6.
-
1999: Bermejo A; Léonce S; Cabedo N; Andreu I; Caignard D H; Atassi G; Cortes D
Semisynthesis and cytotoxicity of styryl-lactone derivatives.
Journal of natural products 1999;62(8):1106-9.
-
1999: Tucker G C; Ferry G; Provent S; Atassi G
In situ activity of gelatinases during Lewis lung carcinoma progression.
Annals of the New York Academy of Sciences 1999;878():534-7.
-
1999: Guillonneau C; PierréA; Charton Y; Guilbaud N; Kraus-Berthier L; Léonce S; Michel A; Bisagni E; Atassi G
Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity.
Journal of medicinal chemistry 1999;42(12):2191-203.
-
1999: Magiatis P; Mitaku S; Skaltsounis A L; Tillequin F; Koch M; Pierré A; Atassi G
Synthesis and cytotoxic activity of 1-alkoxy- and 1-amino-2-hydroxy-1,2-dihydroacronycine derivatives.
Chemical & pharmaceutical bulletin 1999;47(5):611-4.
-
1999: Costes N; Michel S; Tillequin F; Koch M; Pierré A; Atassi G
Chiral dihydroxylation of acronycine: absolute configuration of natural cis-1,2-dihydroxy-1,2-dihydroacronycine and cytotoxicity of (1R,2R)- and (1S,2S)-1,2-diacetoxy-1,2-dihydroacronycine.
Journal of natural products 1999;62(3):490-2.
-
1999: Burbridge M F; West D C; Atassi G; Tucker G C
The effect of extracellular pH on angiogenesis in vitro.
Angiogenesis 1999;3(3):281-8.
-
1998: Magiatis P; Melliou E; Skaltsounis A L; Mitaku S; Léonce S; Renard P; Pierré A; Atassi G
Synthesis and cytotoxic activity of pyranocoumarins of the seselin and xanthyletin series.
Journal of natural products 1998;61(8):982-6.
-
1998: Ferry G; Boutin J A; Hennig P; Genton A; Desmet C; Fauchère J L; Atassi G; Tucker G C
A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects.
European journal of pharmacology 1998;351(2):225-33.
-
1998: Magiatis P; Mitaku S; Skaltsounis A L; Tillequin F; Koch M; Pierré A; Atassi G
Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2-dihydroacronycine series.
Journal of natural products 1998;61(2):198-201.
-
1998: Razafimbelo J; Baudouin G; Tillequin F; Renard P; Léonce S; Pierré A; Atassi G
Synthesis and cytotoxic activity of pyranophenanthridine analogues of fagaronine and acronycine.
Chemical & pharmaceutical bulletin 1998;46(1):34-41.
-
1998: Pierré A; Léonce S; Pérez V; Atassi G
Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines.
Cancer chemotherapy and pharmacology 1998;42(6):454-60.
-
1997: Kraus-Berthier L; Guilbaud N; Jan M; Saint-Dizier D; Rouillon M H; Burbridge M F; Pierré A; Atassi G
Experimental antitumour activity of S 16020-2 in a panel of human tumours.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1881-7.
-
1997: Morris A D; Léonce S; Guilbaud N; Tucker G C; Pérez V; Jan M; Cordi A A; Pierré A; Atassi G
Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo.
Anti-cancer drugs 1997;8(8):746-55.
-
1997: Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon M H; Jan M; Burbridge M; Pierré A; Atassi G
Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.
Anti-cancer drugs 1997;8(3):276-82.
-
1997: Ferry G; Boutin J A; Atassi G; Fauchère J L; Tucker G C
Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries.
Molecular diversity 1997;2(3):135-46.
-
1996: Landras C; Jasztold-Howorko R; Pierré A; Léonce S; Guilbaud N; Kraus-Berthier L; Guillonneau C; Rolland Y; Atassi G; Bisagni E
Synthesis and biological evaluation of 6-(9-hydroxy-5-methyl (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazol-1-yl)picolinic amides as new olivacine derivatives.
Chemical & pharmaceutical bulletin 1996;44(11):2169-72.
-
1996: Elomri A; Skaltsounis A L; Michel S; Tillequin F; Koch M; Rolland Y; Pierré A; Atassi G
Synthesis and cytotoxic activity of acronycine derivatives modified at the pyran ring.
Chemical & pharmaceutical bulletin 1996;44(11):2165-8.
-
1996: Elomri A; Mitaku S; Michel S; Skaltsounis A L; Tillequin F; Koch M; Pierré A; Guilbaud N; Léonce S; Kraus-Berthier L; Rolland Y; Atassi G
Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.
Journal of medicinal chemistry 1996;39(24):4762-6.
-
1996: Dhainaut A; Regnier G; Tizot A; Pierre A; Leonce S; Guilbaud N; Kraus-Berthier L; Atassi G
New purines and purine analogs as modulators of multidrug resistance.
Journal of medicinal chemistry 1996;39(20):4099-108.
-
1996: Mitaku S; Skaltsounis A L; Tillequin F; Koch M; Rolland Y; Pierré A; Atassi G
Synthesis and anti-proliferative activity of 2-hydroxy-1,2-dihydroacronycine glycosides.
Pharmaceutical research 1996;13(6):939-43.
-
1996: Léonce S; Perez V; Casabianca-Pignede M R; Anstett M; Bisagni E; Pierré A; Atassi G
In vitro cytotoxicity of S16020-2, a new olivacine derivative.
Investigational new drugs 1996;14(2):169-80.
-
1996: Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon M H; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Cancer chemotherapy and pharmacology 1996;38(6):513-21.
-
1995: Léonce S; Pierré A; Atassi G
Flow cytometric evaluation of multidrug-resistance circumvention.
Bulletin du cancer 1995;82(2):114-6.
-
1994: Jasztold-Howorko R; Landras C; Pierré A; Atassi G; Guilbaud N; Kraus-Berthier L; Léonce S; Rolland Y; Prost J F; Bisagni E
Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole-1-N- [(dialkylamino)alkyl]carboxamides, a new promising series of antitumor olivacine derivatives.
Journal of medicinal chemistry 1994;37(15):2445-52.
-
1994: Demetzos C; Skaltsounis A L; Michel S; Tillequin F; Koch M; Anstett M; Leonce S; Pierré A; Atassi G
Synthesis and biological activity of 3'-deamino-3'-haloanthracyclines.
Anti-cancer drug design 1994;9(2):129-37.
-
1994: Kraus-Berthier L; Guilbaud N; Peglion J L; Leonce S; Lombet A; Pierre A; Atassi G
In vivo reversal of multidrug resistance by two new dihydropyridine derivatives, S16317 and S16324.
Acta oncologica (Stockholm, Sweden) 1994;33(6):631-7.
-
1993: Pérez V; Pierré A; Léonce S; Anstett M; Atassi G
Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
Anticancer research 1993;13(4):985-90.
-
1993: Pérez V; Pierré A; Léonce S; Anstett M; Prost J F; Atassi G
[In vitro characterization of S9788, a new modulator of multidrug resistance]
Bulletin du cancer 1993;80(4):310-25.
-
1992: Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari J P; Atassi G
Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Biochemical pharmacology 1992;44(9):1707-15.
-
1992: Pierré A; Dunn T A; Kraus-Berthier L; Léonce S; Saint-Dizier D; Régnier G; Dhainaut A; Berlion M; Bizzari J P; Atassi G
In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.
Investigational new drugs 1992;10(3):137-48.
-
1992: Dhainaut A; Régnier G; Atassi G; Pierré A; Léonce S; Kraus-Berthier L; Prost J F
New triazine derivatives as potent modulators of multidrug resistance.
Journal of medicinal chemistry 1992;35(13):2481-96.
-
1992: Pierré A; Pérez V; Léonce S; Boutin J A; Saint-Dizier D; Hautefaye P; Lavielle G; Atassi G
Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
Cancer chemotherapy and pharmacology 1992;29(5):367-74.
-
1992: Cros S; Guilbaud N; Berlion M; Dunn T; Regnier G; Dhainaut A; Atassi G; Bizzari J P
In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model.
Cancer chemotherapy and pharmacology 1992;30(6):491-4.
-
1991: Boutin J A; Clarenc J P; Ferry G; Ernould A P; Remond G; Vincent M; Atassi G
N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes.
European journal of biochemistry / FEBS 1991;201(1):257-63.
-
1991: Pierré A; Kraus-Berthier L; Atassi G; Cros S; Poupon M F; Lavielle G; Berlion M; Bizzari J P
Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.
Cancer research 1991;51(9):2312-8.
-
1991: Atassi G; Berlion M; el Oche Y; Bizzari J P
Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid.
Anticancer research 1991;11(2):975-80.
-
1991: Giorgi-Renault S; Renault J; Gebel-Servolles P; Baron M; Paoletti C; Cros S; Bissery M C; Lavelle F; Atassi G
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
Journal of medicinal chemistry 1991;34(1):38-46.
-
1991: Tassin J P; Boutin J A; Ernould A P; Atassi G
[Farnesyltransferase as target for non-cytotoxic anti-cancer agents: first steps]
Comptes rendus des séances de la Société de biologie et de ses filiales 1991;185(5):306-11.
Sign-in to see more
